Oncolytic Virus Therapy Market is estimated to grow at a 24.5% CAGR during the forecast period for 2025-2034. In recent decades, the healthcare burden of Cancer increasing rapidly with an increasing incidence rate. The massive investment in research and development has been implemented to find innovative drugs/therapy/Immuno oncology solutions to cure cancer. Some of them gaining interest include oncolytic viruses therapy, stem cell therapies,...
Report ID: 1087 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Therapeutic Plasma Exchange Market is expected to grow at an 5.5% CAGR during the forecast period for 2025-2034. Plasma exchange is a biological procedure that removes large-molecular-weight substances such as harmful antibodies from the plasma. In this procedure, a large portion of plasma containing abnormal matter and toxins are removed from the components of WBCs, RBCs, and platelets and then replaced with replacement fluid, like fresh froz...
Report ID: 1120 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Veterinary Antibiotics Market Size is valued at USD 4.99 Billion in 2024 and is predicted to reach USD 6.95 Billion by the year 2034 at a 3.5 % CAGR during the forecast period for 2025-2034. Key Industry Insights & Findings from the Report: The market is in great demand due to the increasing number of pet diseases worldwide, which leads to market growth. The need for efficient veterinary antibiotic treatments is driven by the rising in...
Report ID: 1128 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Global Biosimilar Monoclonal Antibodies Market Size is valued at USD 7.8 Billion in 2024 and is predicted to reach USD 32.1 Billion by the year 2034 at a 15.3% CAGR during the forecast period for 2025-2034. Key Industry Insights & Findings from the Report: The rising occurence of chronic diseases like cancer, autoimmune disorders, and inflammatory diseases is driving the biosimilar monoclonal antibodies market. The te...
Report ID: 1218 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Global Non-Invasive Aesthetic Treatment Market size is valued at USD 25.7 Bn in 2024 and is predicted to reach USD 63.8 Bn by the year 2034 at a 9.9% CAGR during the forecast period for 2025 to 2034. Non-Invasive Aesthetic Treatment Market Size, Share & Trends Analysis Report By Distribution by Type of Procedure (Injectable (Polymer Filler, Collagen, Botulinum Toxin, Hyaluronic Acid, and Calcium Hydroxylapatite), Skin Rejuvenation (Laser Ski...
Report ID: 3092 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031. Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. The abnormal growth of call is called cancer. Cancer is the second leading cause of death across the globe. Ma...
Report ID: 1078 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Global Adalimumab Biosimilar Market Size is estimated to grow at the CAGR of 23.0% during the forecast period for 2025-2034. Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor (TNF), which is a soluble inflammatory cytokine, to treat autoimmune disorders. Adalimumab binds to TNF-alpha (TNF-), blocking it from activating TNF receptors, which are responsible for autoimmune disorders' inflammatory responses. Adalimum...
Report ID: 1058 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
The Etanercept Biosimilar Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034 at an 17.8% CAGR during the forecast period for 2025-2034. Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor-alpha (TNF-α) inhibitor approved for the treatment of rhe...
Report ID: 1068 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Rituximab Biosimilar Market is expected to grow at a 12.3% CAGR during the forecast period for 2025-2034. Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the standard and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, as well as an autoimmune disorder such as Rheumatoid arthritis. Rituximab i...
Report ID: 1081 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Synthetic Lethality-based Drugs and Targets Market Size is predicted to witness a 14.5% CAGR during the forecast period for 2025-2034. Synthetic lethality refers to a genetic and cancer treatment notion in which the simultaneous dysfunction of two genes results in cell death, whereas the dysfunction of either gene alone does not have the same effect. This method is employed to create precise cancer treatments that take advantage of parti...
Report ID: 2657 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Pharmaceuticals